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INTRODUCTION 
Today, there is a growing awareness that the adipose tissue 
is an active endocrine and paracrine organ producing multi-
ple signaling proteins designated adipokines (1-6). There is 
evidence indicating that the neurotrophin nerve growth factor 
(NGF) is also produced by adipose tissue (2,7,8), whereas to 
the best of our knowledge, there is only one paper (9) revealing 
adipose-derived brain-derived neurotrophic factor (BDNF), 
another important member of the protein family of neuro-
trophins. Neurotrophins exert their action not only on nerve 
cells, but also act on a number of other cell types including 
immune cells (10) and pancreatic beta cells (11). Recent stud-
ies also demonstrate that NGF and BDNF exert metabotrophic 
effects on glucose and lipid metabolism (5,11,12) and that the 
plasma concentration of NGF and/or BDNF of subjects with 
coronary atherosclerosis (7), acute coronary syndrome (13), 
metabolic syndrome (7,14,15) and obesity/diabetes (15,16) is 
significantly altered (also see 17,18). Hence the question was
asked whether the presence of BDNF might also be altered 
in both white and brown adipose tissues (WAT and BAT, 
respectively). 
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Since leptin discovery in 1994, an extensive body of work has been demonstrating that adipose tissue (mainly its white phenotype) 
expresses not only metabolic, but also endocrine and paracrine phenotypes, particularly in adipobiology of disease. This new 
biology is achieved predominantly through secretion of adipokines, which include more than hundred highly active signaling 
proteins. However, studies on adipobiology of neurotrophins have recently emerged, nerve growth factor being one example of 
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Figure. The concentration of BDNF in epicardial white adipose tissue (WAT) and brown adipose tissue (BAT) of controls com-
pared to the concentration of BDNF in stressed mice (Stress) and diabetic rats (STZ). The BDNF concentration is expressed as 
pg/g of tissue and all assays were performed in duplicate. Data are represented as pg/g wet tissue and all assays were performed 
in duplicate.
 Stress was produced in adult male mice of Swiss CD-1 
strain first by social isolation for 8 weeks followed by hous-
ing with a fellow male mice of the same strain and age for 60 
min, isolated for the same time period. This profile leads to
aggressive behavior and fighting. Intact male subjects of the
same strain and age were used as control group. 
 Diabetes was induced in Sprague Dawley male rats by a 
single intravenous injection of streptozotocin (STZ) at a dose 
of 60 mg/kg dissolved in PBS (17,18). Rats were considered 
diabetic and included in the study if they had a fasting plasma 
glucose level >350 mg/dl. An equal number of male rats re-
ceived a physiological solution and served as controls. 
 Stressed and diabetic animals and their respective controls 
were sacrificed with an overdose of Nembutal, and WAT of
the epicardial region and BAT of the interscapular region were 
taken and used for BDNF immunoenzymatic assay, and for 
paraformaldehyde fixation for histological analysis (data not
shown). 
 Brain-derived neurotrophic factor was measured by an 
ELISA kit, "BDNF Emax Immunoassay System number 
G7611" by Promega, (Madison, WI, USA), following the 
manufacturer’s instructions.
 For housing, care and experimental procedures, we fol-
lowed the guidelines indicated by Intramural Committee 
and Institutional Guidelines in accordance with National and 
International law (EEC council directive 86/609, OJ L 358, 
1, 12 December1987) and the NIH principles of laboratory 
animal care (NIH publication no. 85-23, revised 1985). 
WAT AND BAT SYNTHESIZE AND STORE BDNF
Diabetic rats displayed enhanced levels of BDNF in the adi-
pose tissues analyzed (p<0.05). Specifically,ANOVArevealed
a mild increase in both WAT and BAT (p=0.08 in post-hocs). 
However, BDNF presence was not altered in stressed mice 
(Figure). 
 The cellular source of BDNF in WAT and BAT is not known. 
Since the adipose tissue contains mast cells (19), and these cells 
are known to be both source of and target for NGF (10,20), we 
investigated the number of mast cells in WAT and BAT (data 
not shown). 
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BDNF IS A NEW ADIPOKINE 
A novel aspect of our study is the observation that BDNF 
is found in both BAT and WAT of mice and rats, suggesting 
that BDNF might be a new member of the adipokine family 
of proteins. Whether NGF and BDNF play similar, overlap-
ping or different roles in adipose tissue is at present not clear. 
Nevertheless, BDNF  is known to be a potent metabokine, 
that is, exerts various metabotrophic effects, including ano-
rexigenic and anti-diabetic effects (5,11,12,21-26). Note that 
in addition to NGF (2,7,8), BDNF (9 and present data) and 
other neurotrophic factors (5,26), various neuropeptides such 
as agouti protein, somatostatin, adrenomedullin, calcitonin 
gene-related peptide, substance P and neuropeptide tyrosine 
(NPY) (27-33) as well as receptors for neuropeptides and hy-
pothalamic and pituitary hormones are expressed in adipose 
tissue (34-36), raising a hypothesis of neuroendocrine potential 
of adipose tissue.
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